Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives
- 5 March 2014
- journal article
- review article
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 16 (4) , 1-8
Abstract
Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not respond (primary non-response) or will lose response to the drug over time (secondary non-response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. This review emphasizes interesting and important new findings, and provides an updated overview, on the subject of therapeutic drug monitoring. While exploring the hypothesis that “one size does not fit all”, we focused on the first prospective studies investigating the novel approach in IBD of ‘target concentration adjusted dosing’ and personalized medicine.Keywords
This publication has 49 references indexed in Scilit:
- UEG Week 2013 Oral PresentationsUnited European Gastroenterology Journal, 2013
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-AnalysisAmerican Journal of Gastroenterology, 2013
- Value of drug level testing and antibody assays in optimising biological therapyFrontline Gastroenterology, 2012
- Paradoxical inflammation induced by anti-TNF agents in patients with IBDNature Reviews Gastroenterology & Hepatology, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel diseaseJournal of Gastroenterology, 2011
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002